<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font25">the </span>
   <span class="font17">for </span>
   <span class="font17">infections </span>
   <span class="font17">viral </span>
   <span class="font16">were </span>
   <span class="font16">with </span>
   <span class="font15">was </span>
   <span class="font14">infection </span>
   <span class="font14">The </span>
   <span class="font13">(n=) </span>
   <span class="font13">after </span>
   <span class="font13">allo-HCT </span>
   <span class="font13">from </span>
   <span class="font13">{background </span>
   <span class="font13">(.–.) </span>
   <span class="font13">incidence </span>
   <span class="font13">patients </span>
   <span class="font12">EBV </span>
   <span class="font12">cell </span>
   <span class="font12">;():–. </span>
   <span class="font12">are </span>
   <span class="font12">risk </span>
   <span class="font12">other </span>
   <span class="font12">margin </span>
   <span class="font12">al. </span>
   <span class="font12">{border-style </span>
   <span class="font12">(n=), </span>
   <span class="font12">CMV </span>
   <span class="font12">acute </span>
   <span class="font12">hematopoietic </span>
   <span class="font12">px;} </span>
   <span class="font12">treatment </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">antiviral </span>
   <span class="font11">children </span>
   <span class="font11">most </span>
   <span class="font11">not </span>
   <span class="font11">stem </span>
   <span class="font11">HCT </span>
   <span class="font11">auto-HCT </span>
   <span class="font11">that </span>
   <span class="font11">(.%) </span>
   <span class="font11">significant </span>
   <span class="font11">specific </span>
   <span class="font11">transplantation </span>
   <span class="font11">used </span>
   <span class="font11">Infections </span>
   <span class="font11">infection. </span>
   <span class="font11">therapy </span>
   <span class="font11">virus </span>
   <span class="font11">virus; </span>
   <span class="font11">EBV-DNA-emia </span>
   <span class="font11">Marrow </span>
   <span class="font11">have </span>
   <span class="font11">leukemia </span>
   <span class="font11">observed </span>
   <span class="font11">pediatric </span>
   <span class="font11">respiratory </span>
   <span class="font11">study </span>
   <span class="font11">ADV </span>
   <span class="font11">BKV </span>
   <span class="font11">factors </span>
   <span class="font11">these </span>
   <span class="font11">CMV, </span>
   <span class="font11">European </span>
   <span class="font11">Infect </span>
   <span class="font11">before </span>
   <span class="font11">during </span>
   <span class="font11">n=; </span>
   <span class="font11">patients. </span>
   <span class="font11">primary </span>
   <span class="font11">unrelated </span>
   <span class="font11">Transplant. </span>
   <span class="font11">Viral </span>
   <span class="font11">development </span>
   <span class="font11">diagnosis </span>
   <span class="font11">donor; </span>
   <span class="font11">drugs </span>
   <span class="font11">human </span>
   <span class="font11">infection, </span>
   <span class="font11">infectious </span>
   <span class="font11">matched </span>
   <span class="font11">patients, </span>
   <span class="font11">reactivation </span>
   <span class="font11">rituximab </span>
   <span class="font10">(HR=.; </span>
   <span class="font10">Ganciclovir </span>
   <span class="font10">MSD </span>
   <span class="font10">Risk </span>
   <span class="font10">all </span>
   <span class="font10">allogeneic </span>
   <span class="font10">cases </span>
   <span class="font10">days </span>
   <span class="font10">episodes </span>
   <span class="font10">frequent </span>
   <span class="font10">influenza </span>
   <span class="font10">mortality </span>
   <span class="font10">period </span>
   <span class="font10">pre-emptive </span>
   <span class="font10">px; </span>
   <span class="font10">this </span>
   <span class="font10">while </span>
   <span class="font10">{font-family </span>
   <span class="font10">&amp;lt;. </span>
   <span class="font10">All </span>
   <span class="font10">Department </span>
   <span class="font10">EBV, </span>
   <span class="font10">HSV, </span>
   <span class="font10">NoV </span>
   <span class="font10">Pediatric </span>
   <span class="font10">Table </span>
   <span class="font10">This </span>
   <span class="font10">University </span>
   <span class="font10">VZV, </span>
   <span class="font10">analysis </span>
   <span class="font10">complications </span>
   <span class="font10">cumulative </span>
   <span class="font10">disease </span>
   <span class="font10">donor </span>
   <span class="font10">first </span>
   <span class="font10">font-size </span>
   <span class="font10">median </span>
   <span class="font10">occurred </span>
   <span class="font10">patient </span>
   <span class="font10">prevent </span>
   <span class="font10">reported </span>
   <span class="font10">time </span>
   <span class="font10">treated </span>
   <span class="font10">Blood </span>
   <span class="font10">Bone </span>
   <span class="font10">Cidofovir </span>
   <span class="font10">Conference </span>
   <span class="font10">Dis. </span>
   <span class="font10">HHV-, </span>
   <span class="font10">Infection </span>
   <span class="font10">Infectious </span>
   <span class="font10">RhV, </span>
   <span class="font10">allo-HCT, </span>
   <span class="font10">bold </span>
   <span class="font10">can </span>
   <span class="font10">cause </span>
   <span class="font10">conditioning; </span>
   <span class="font10">data </span>
   <span class="font10">death </span>
   <span class="font10">did </span>
   <span class="font10">double; </span>
   <span class="font10">guidelines </span>
   <span class="font10">has </span>
   <span class="font10">infection: </span>
   <span class="font10">lymphoblastic </span>
   <span class="font10">nationwide </span>
   <span class="font10">recommended </span>
   <span class="font10">than </span>
   <span class="font10">total </span>
   <span class="font10">use </span>
   <span class="font10">viruses </span>
   <span class="font10">.StyczynskiJ, </span>
   <span class="font10">ALL </span>
   <span class="font10">Analysis </span>
   <span class="font10">CMV-IgG </span>
   <span class="font10">Collegium </span>
   <span class="font10">Epstein–Barr </span>
   <span class="font10">FLUAV, </span>
   <span class="font10">For </span>
   <span class="font10">HPIV, </span>
   <span class="font10">Medical </span>
   <span class="font10">NoV, </span>
   <span class="font10">RSV, </span>
   <span class="font10">RV, </span>
   <span class="font10">a/cGVHD, </span>
   <span class="font10">any </span>
   <span class="font10">been </span>
   <span class="font10">bone </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cases, </span>
   <span class="font10">evidence </span>
   <span class="font10">factor </span>
   <span class="font10">four </span>
   <span class="font10">given </span>
   <span class="font10">graft </span>
   <span class="font10">hMPV, </span>
   <span class="font10">host </span>
   <span class="font10">infections. </span>
   <span class="font10">latent </span>
   <span class="font10">lymphoma; </span>
   <span class="font10">multicenter </span>
   <span class="font10">one </span>
   <span class="font10">over </span>
   <span class="font10">post-transplant </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">recipients </span>
   <span class="font10">shown </span>
   <span class="font10">solid; </span>
   <span class="font10">survival </span>
   <span class="font10">symptomatic </span>
   <span class="font10">undergoing </span>
   <span class="font10">using </span>
   <span class="font10">versus </span>
   <span class="font10">within </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(Table </span>
   <span class="font10">(for </span>
   <span class="font10">After </span>
   <span class="font10">BKV, </span>
   <span class="font10">Cell </span>
   <span class="font10">Copernicus </span>
   <span class="font10">Czyzewski </span>
   <span class="font10">Drug </span>
   <span class="font10">FLUAV </span>
   <span class="font10">Factor </span>
   <span class="font10">Factors </span>
   <span class="font10">Foscarnet </span>
   <span class="font10">GVHD </span>
   <span class="font10">HCT, </span>
   <span class="font10">Hematology </span>
   <span class="font10">Hodgkin </span>
   <span class="font10">IVIG </span>
   <span class="font10">MMUD </span>
   <span class="font10">MUD </span>
   <span class="font10">Nicolaus </span>
   <span class="font10">Non-Hodgkin </span>
   <span class="font10">Number </span>
   <span class="font10">Oncology </span>
   <span class="font10">PCR </span>
   <span class="font10">PVB </span>
   <span class="font10">Survival </span>
   <span class="font10">Transpl </span>
   <span class="font10">adolescents </span>
   <span class="font10">also </span>
   <span class="font10">authors </span>
   <span class="font10">available </span>
   <span class="font10">between </span>
   <span class="font10">case </span>
   <span class="font10">caused </span>
   <span class="font10">cidofovir </span>
   <span class="font10">courier; </span>
   <span class="font10">currently </span>
   <span class="font10">cytomegalovirus </span>
   <span class="font10">day </span>
   <span class="font10">deaths </span>
   <span class="font10">defined </span>
   <span class="font10">diagnosed </span>
   <span class="font10">disease; </span>
   <span class="font10">doi:./bmt.. </span>
   <span class="font10">doi:./tid...issue- </span>
   <span class="font10">due </span>
   <span class="font10">em; </span>
   <span class="font10">epidemiology, </span>
   <span class="font10">following </span>
   <span class="font10">herpesvirus </span>
   <span class="font10">higher </span>
   <span class="font10">immunosuppressive </span>
   <span class="font10">impact </span>
   <span class="font10">infections, </span>
   <span class="font10">leukemia; </span>
   <span class="font10">lymphoproliferative </span>
   <span class="font10">management </span>
   <span class="font10">more </span>
   <span class="font10">multiple </span>
   <span class="font10">our </span>
   <span class="font10">performed </span>
   <span class="font10">pharmacotherapy </span>
   <span class="font10">preceded </span>
   <span class="font10">pt;} </span>
   <span class="font10">rate </span>
   <span class="font10">recipient </span>
   <span class="font10">recipients. </span>
   <span class="font10">setting. </span>
   <span class="font10">sibling </span>
   <span class="font10">statistically </span>
   <span class="font10">such </span>
   <span class="font10">syncytial </span>
   <span class="font10">therapies </span>
   <span class="font10">therapy. </span>
   <span class="font10">there </span>
   <span class="font10">transplant </span>
   <span class="font10">transplantation. </span>
   <span class="font10">two </span>
   <span class="font10">varicella-zoster </span>
   <span class="font10">which </span>
   <span class="font10">work </span>
   <span class="font10">yes </span>
  </p>
 </body>
</html>
